• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗重型和中间型β地中海贫血患者的生存率及其近年变化趋势。

The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran.

机构信息

Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

Department of Epidemiology and Biostatistics, Iranshahr University of Medical Sciences, Iranshahr, Iran.

出版信息

Epidemiol Health. 2018;40:e2018048. doi: 10.4178/epih.e2018048. Epub 2018 Oct 3.

DOI:10.4178/epih.e2018048
PMID:30336663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6335498/
Abstract

OBJECTIVES

Thalassemia is a common genetic disease in Iran, especially in the north and south of Iran. The present study sought to determine the survival rate of patients with thalassemia in highly endemic regions of Iran and its variation in patients born before and after 1971.

METHODS

The present historical cohort study extracted data from the health records of patients with beta-thalassemia major, beta-thalassemia intermedia, and sickle beta-thalassemia who had presented to thalassemia treatment centers in the past years. The collected data were analyzed using the Kaplan-Meier test, the log-rank test, and the chi-square test.

RESULTS

Of the total of 5,491 medical records (2,647 men and 2,634 women; mean age, 23.81±11.32 years), 3,936 belonged to patients with beta-thalassemia major, and 999 and 89 to patients with beta-thalassemia intermedia and sickle beta-thalassemia, respectively. In 467 cases, the type of thalassemia was not clear. The cumulative survival rate was calculated as 0.92, 0.83, 0.74, and 0.51 by ages 25, 35, 45, and 55, respectively. The hazard ratio of death was 4.22 (p<0.05) for beta-thalassemia major and 0.77 for beta-thalassemia intermedia (p=0.70). It was calculated as 1.45 for men patients and as 3.82 for single patients.

CONCLUSIONS

The present study showed relatively high survival rates in patients with thalassemia. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including women gender, a higher level of education, being married, and living in metropolises decreased the risk of death at younger ages and improved survival.

摘要

目的

地中海贫血是伊朗常见的遗传性疾病,尤其是在伊朗北部和南部。本研究旨在确定伊朗高度流行地区地中海贫血患者的生存率及其在 1971 年前和后出生的患者中的变化。

方法

本历史队列研究从过去几年中在地中海贫血治疗中心就诊的重型β地中海贫血、中间型β地中海贫血和镰状β地中海贫血患者的健康记录中提取数据。使用 Kaplan-Meier 检验、对数秩检验和卡方检验对收集的数据进行分析。

结果

在总共 5491 份病历中(2647 名男性和 2634 名女性;平均年龄 23.81±11.32 岁),3936 份属于重型β地中海贫血患者,999 份和 89 份分别属于中间型β地中海贫血和镰状β地中海贫血患者。在 467 例中,地中海贫血的类型不明确。按年龄 25、35、45 和 55 岁计算,累积生存率分别为 0.92、0.83、0.74 和 0.51。重型β地中海贫血患者的死亡风险比为 4.22(p<0.05),中间型β地中海贫血患者的死亡风险比为 0.77(p=0.70)。男性患者的风险比为 1.45,单身患者的风险比为 3.82。

结论

本研究显示地中海贫血患者的生存率相对较高。在较贫困地区(扎黑丹和伊兰沙赫尔),患者的生存状况不佳。女性性别、较高的教育水平、已婚和居住在大都市等因素降低了年轻患者死亡的风险,提高了生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/8462f5717ed3/epih-40-e2018048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/fa744b5e8629/epih-40-e2018048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/5a5367a5f40f/epih-40-e2018048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/8462f5717ed3/epih-40-e2018048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/fa744b5e8629/epih-40-e2018048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/5a5367a5f40f/epih-40-e2018048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/6335498/8462f5717ed3/epih-40-e2018048f3.jpg

相似文献

1
The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran.伊朗重型和中间型β地中海贫血患者的生存率及其近年变化趋势。
Epidemiol Health. 2018;40:e2018048. doi: 10.4178/epih.e2018048. Epub 2018 Oct 3.
2
The survival analysis of beta thalassemia major patients in South East of Iran.伊朗东南部重型β地中海贫血患者的生存分析
Saudi Med J. 2008 Jul;29(7):1031-5.
3
Comparison of Quality of Life in Patients with β-Thalassemia Intermedia and β-Thalassemia Major in Southern Iran.伊朗南部中间型β地中海贫血和重型β地中海贫血患者生活质量比较
Hemoglobin. 2017 May;41(3):169-174. doi: 10.1080/03630269.2017.1340307. Epub 2017 Jul 25.
4
Malignancies in patients with beta-thalassemia major and beta-thalassemia intermedia: a multicenter study in Iran.重型β地中海贫血和中间型β地中海贫血患者的恶性肿瘤:伊朗的一项多中心研究。
Pediatr Blood Cancer. 2009 Dec;53(6):1064-7. doi: 10.1002/pbc.22144.
5
β-Thalassemia in Iran: Things Everyone Needs to Know About This Disease.伊朗的β地中海贫血:关于这种疾病每个人都需要了解的事情。
Hemoglobin. 2019 May;43(3):166-173. doi: 10.1080/03630269.2019.1628774. Epub 2019 Jul 4.
6
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.伊朗β地中海贫血中输血与羟基脲治疗的成本效益研究
Hematology. 2018 Aug;23(7):417-422. doi: 10.1080/10245332.2017.1404262. Epub 2017 Nov 21.
7
Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan.台湾北部重型β地中海贫血患者的生存率、死亡率及并发症
Pediatr Blood Cancer. 2007 May;48(5):550-4. doi: 10.1002/pbc.21028.
8
Molecular basis of thalassemia intermedia in Iran.伊朗中间型地中海贫血的分子基础。
Hemoglobin. 2008;32(5):462-70. doi: 10.1080/03630260802341851.
9
Hematopoietic stem cell transplantation for beta-thalassemia major: experience in south of Iran.重型β地中海贫血的造血干细胞移植:伊朗南部的经验
Transplant Proc. 2004 Oct;36(8):2509-10. doi: 10.1016/j.transproceed.2004.08.134.
10
The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?重型地中海贫血和中间型地中海贫血预期寿命相当的时代:是否是时候重新审视重型与中间型的二分法了?
Br J Haematol. 2017 Jan;176(1):124-130. doi: 10.1111/bjh.14381. Epub 2016 Oct 17.

引用本文的文献

1
Correlation of Magnesium Level with Cardiac and Hepatic Hemosiderosis Measured by T2*MRI Technique and Age in Patients with Thalassemia Major.重型地中海贫血患者镁水平与通过T2*MRI技术测量的心脏和肝脏含铁血黄素沉着症及年龄的相关性
Int J Hematol Oncol Stem Cell Res. 2023 Oct 1;17(4):224-230. doi: 10.18502/ijhoscr.v17i4.13912.
2
Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection.系统文献综述显示镰状细胞病和镰状细胞性状的全球患病率及出生患病率数据存在差距:呼吁采取行动扩大并统一数据收集工作。
J Clin Med. 2023 Aug 25;12(17):5538. doi: 10.3390/jcm12175538.
3

本文引用的文献

1
Analysis of survival data in thalassemia patients in Shiraz, Iran.伊朗设拉子地中海贫血患者生存数据分析。
Epidemiol Health. 2015 Jul 7;37:e2015031. doi: 10.4178/epih/e2015031. eCollection 2015.
2
Survival analysis and its associated factors of Beta thalassemia major in hamadan province.哈马丹省重型β地中海贫血的生存分析及其相关因素
Iran J Med Sci. 2015 May;40(3):233-9.
3
[Beta-thalassemias: molecular, epidemiological, diagnostical and clinical aspects].[β地中海贫血:分子、流行病学、诊断及临床方面]
Accelerated atherosclerosis in beta-thalassemia.
β-地中海贫血导致的动脉粥样硬化加速。
Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1133-H1143. doi: 10.1152/ajpheart.00306.2023. Epub 2023 Sep 8.
4
Economic burden of adult patients with β-thalassaemia major in mainland China.β-重型地中海贫血成年患者的经济负担。
Orphanet J Rare Dis. 2023 Aug 29;18(1):252. doi: 10.1186/s13023-023-02858-4.
5
Investigating the effectiveness of Case-Based Technology-Enhanced workshops (e-Flipped vs. Online) among health worker nurses during the COVID-19 pandemic.调查基于案例的技术增强型研讨会(翻转课堂与在线教学)在 COVID-19 大流行期间对卫生工作者护士的效果。
Nurs Open. 2023 Apr;10(4):2329-2337. doi: 10.1002/nop2.1486. Epub 2022 Nov 23.
6
Thalassemia Intermedia: Chelator or Not?中间型地中海贫血:螯合剂治疗,还是不治疗?
Int J Mol Sci. 2022 Sep 5;23(17):10189. doi: 10.3390/ijms231710189.
7
Bone Mineral Density, Serum Calcium, and Vitamin D Levels in Adult Thalassemia Major Patients: Experience From a Single Center in Eastern India.成年重型地中海贫血患者的骨矿物质密度、血清钙和维生素D水平:来自印度东部一个单一中心的经验
Cureus. 2022 Jul 9;14(7):e26688. doi: 10.7759/cureus.26688. eCollection 2022 Jul.
8
Prevalence and risk factors of fractures in transfusion dependent thalassemia - A Hong Kong Chinese population cohort.输血依赖型地中海贫血患者骨折的患病率及危险因素:一项香港华人人群队列研究。
Endocrinol Diabetes Metab. 2022 Jul;5(4):e340. doi: 10.1002/edm2.340. Epub 2022 Apr 30.
Ann Biol Clin (Paris). 2014 Nov-Dec;72(6):639-68. doi: 10.1684/abc.2014.1015.
4
Epidemiology of hemoglobinopathies and thalassemias in individuals referred to the haematology research centre, Shiraz University of Medical Sciences, Shiraz, Iran from 2006 to 2011.2006年至2011年转诊至设拉子医科大学血液学研究中心的伊朗设拉子血红蛋白病和地中海贫血的流行病学情况。
Hemoglobin. 2014;38(4):287-8. doi: 10.3109/03630269.2014.921791. Epub 2014 Jun 18.
5
β-Thalassemia Intermedia: A Bird's-Eye View.中间型β地中海贫血:鸟瞰
Turk J Haematol. 2014 Mar;31(1):5-16. doi: 10.4274/Tjh.2014.0032. Epub 2014 Mar 5.
6
Distribution of β-Globin Gene Mutations in Thalassemia Minor Population of Kerman Province, Iran.伊朗克尔曼省轻型地中海贫血人群中β-珠蛋白基因突变的分布
Iran J Public Health. 2010;39(2):69-76. Epub 2010 Jun 30.
7
Complications of β-thalassemia intermedia in Iran during 1996-2010 (single-center study).1996 - 2010年伊朗中间型β地中海贫血的并发症(单中心研究)
Pediatr Hematol Oncol. 2011 Sep;28(6):497-508. doi: 10.3109/08880018.2011.572144. Epub 2011 Jul 5.
8
Causes for hospitalization and death in Iranian patients with β-thalassemia major.伊朗重型β地中海贫血患者的住院及死亡原因。
Pediatr Hematol Oncol. 2011 Mar;28(2):134-9. doi: 10.3109/08880018.2010.503336. Epub 2010 Aug 26.
9
Beta-thalassemia.β-地中海贫血。
Orphanet J Rare Dis. 2010 May 21;5:11. doi: 10.1186/1750-1172-5-11.
10
The survival analysis of beta thalassemia major patients in South East of Iran.伊朗东南部重型β地中海贫血患者的生存分析
Saudi Med J. 2008 Jul;29(7):1031-5.